Status:
UNKNOWN
Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP)
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Benign Prostatic Hyperplasia
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Enucleation of the prostate equips technology (usually laser) to effectively treat lower urinary tract symptoms associated with benign prostate hyperplasia (BPH). The holmium: yttrium-aluminum-garnet ...
Detailed Description
Enucleation of the prostate equips technology (usually laser) to effectively treat lower urinary tract symptoms associated with benign prostate hyperplasia (BPH). The holmium: yttrium-aluminum-garnet ...
Eligibility Criteria
Inclusion
- Patients with symptomatic benign prostate hyperplasia : urinary retention, acute renal failure (post-renal), refractory hematuria, repeated urinary tract infections, refractory symptoms.
- Prostates between 50-300 grams,
- IPSS ≥ 8,
- Inadequate response to previous medical treatments,
- Qmax \< 15 ml/sec and
- Providing informed consent
Exclusion
- History of prostatic surgery,
- History of prostate or bladder cancer,
- Neurogenic bladder,
- Urethral stricture,
- Anticoagulant therapy (aspirin permitted), not ceased during surgery
- Patients unfit for surgery
Key Trial Info
Start Date :
September 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04807296
Start Date
September 8 2021
End Date
September 1 2024
Last Update
October 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier de l'Université de Montréal
Montreal, Canada